How Anticholinergic Drugs Might Promote Alzheimer's Disease: More Amyloid-β and Less Phosphatidylcholine

J Alzheimers Dis. 2015;46(4):983-7. doi: 10.3233/JAD-150290.

Abstract

Drugs that block muscarinic cholinergic neurotransmission in the brain can, as a consequence, increase the formation of amyloid-β, and decrease brain levels of phosphatidylcholine (by slowing its synthesis and accelerating its turnover). Both of these effects might cause a decrease in brain synapses, as characterizes and probably underlies the memory disorder of early Alzheimer's disease.

Keywords: Acetylcholine; amyloid; choline; neurotransmission; synapses; synaptic membrane.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • Cholinergic Antagonists / pharmacology
  • Cholinergic Antagonists / therapeutic use*
  • Humans
  • Phosphatidylcholines / metabolism*

Substances

  • Amyloid beta-Peptides
  • Cholinergic Antagonists
  • Phosphatidylcholines